Mar 27, 2020
Nordic Nanovector ASA Publishes 2019 Annual Report
Mar 24, 2020
Nordic Nanovector ASA - Allocation of PSUs
Mar 23, 2020
Nordic Nanovector Appoints Dr Dominic Smethurst as Interim Chief Medical Officer
Mar 10, 2020
Nordic Nanovector ASA - Financial calendar
Feb 27, 2020
Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2019
Feb 27, 2020
Nordic Nanovector ASA - resultat for fjerde kvartal og helar 2019
Dec 18, 2019
Nordic Nanovector Awarded NOK 12 Million in Funding From the Norwegian Research Council to Advance Alpha37, a Targeted Alpha Therapy for B-cell Cancers
Dec 12, 2019
Nordic Nanovector Provides Update on LYMRIT 37-05 Phase 1 DLBCL Trial
Dec 11, 2019
Nordic Nanovector ASA: Allocation of PSUs
Dec 04, 2019
Nordic Nanovector: New preclinical Data Offer Insights Into Enhancing Betalutin®-Based Therapies in NHL
Nov 19, 2019
Nordic Nanovector ASA - Results for the Third Quarter 2019
Nov 15, 2019
Nordic Nanovector to Participate in Four Upcoming Investor Conferences
Oct 24, 2019
Nordic Nanovector ASA - Resolution not to Proceed With a Repair Offering
Oct 23, 2019
Nordic Nanovector ASA - Tranche 1 Share Capital Increase Registered
Oct 21, 2019
Nordic Nanovector ASA - Tranche 2 Share Capital Increase Registered
Oct 18, 2019
Nordic Nanovector - Private Placement Successfully Completed
Oct 09, 2019
Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Oct 07, 2019
Nordic Nanovector Signs Global Clinical and Commercial Agreement With ITM for the Supply of No-carrier-added Lutetium-177
Sep 19, 2019
Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options
Aug 29, 2019
Nordic Nanovector ASA: Invitation to R&D Day in Oslo and Webcast